JZJing De Zhu

Jing De Zhu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jing De Zhu has a total of 52 co-authors. Here are the top co-authors by number of shared publications:

  • Jian Yu

    The State-key Laboratory for Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai Jiao Tong University, LN 2200/25, Xietu Road, Shanghai 200032, China

    4 shared publications
  • Peng Wang

    Laboratory of Cancer Epigenetics and Gene Therapy, The State-Key Laboratory for Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai Jiaotong University, LN 2200/25, Xietu Road, Shanghai 200032, China

    4 shared publications
  • Hong Yu Zhang

    Laboratory of Cancer Epigenetics and Gene Therapy, The State-Key Laboratory for Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai Jiaotong University, LN 2200/25, Xietu Road, Shanghai 200032, China

    3 shared publications
  • Jun Gu

    The State-key Laboratory for Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai Jiao Tong University, LN 2200/25, Xietu Road, Shanghai 200032, China

    3 shared publications
  • Hong-Yu Zhang

    2 shared publications
  • Qi Fei

    Laboratory of Cancer Epigenetics and Gene Therapy, The State-Key Laboratory for Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai Jiaotong University, LN 2200/25, Xietu Road, Shanghai 200032, China

    2 shared publications

Latest Publications

  • Open Access

    Use of DNA Methylation for Cancer Detection and Molecular Classification

    by Jingde Zhu, Xuebiao Yao

    Use of DNA Methylation for Cancer Detection and Molecular Classification Cancer DNA Methylation;Epigenetics;Methylation Specific PCR; Conjugation of the methyl group at the fifth carbon of cytosines within the palindromic dinucleotide 5'-CpG-3' sequence (DNA methylation) is the best studied epigenetic mechanism, which acts together with other epigenetic entities: histone modification, chromatin remodeling and microRNAs to shape the chromatin structure of DNA according to its functional state. The cancer genome is frequently characterized by hypermethylation of specific genes concurrently with an overall decrease in the level of 5-methyl cytosine, the pathological implication of which to the cancerous state has been well established. While the latest genome-wide technologies have been applied to classify and interpret the epigenetic layer of gene regulation in the physiological and disease states, the epigenetic testing has also been seriously explored in clinical practice for early detection, refining tumor staging and predicting disease recurrence. This critique reviews the latest research findings on the use of DNA methylation in cancer diagnosis, prognosis and staging/classification.


  • Transcription of the putative tumor suppressor gene HCCS1 requires binding of ETS-2 to its consensus near the transcription start site

    by Jing De Zhu, Qi Fei, Peng Wang, Fei Lan, Da Qin Mao, Hong Yu Zhang, Xue Biao Yao


  • The altered DNA methylation pattern and its implications in liver cancer

    by Jing De Zhu

    DNA methylation is the most intensively studied epigenetic phenomenon, disturbances of which result in changes in gene transcription, thus exerting drastic imparts onto biological behaviors of cancer. Both the global demethylation and the local hypermethylation have been widely reported in all types of tumors, providing both challenges and opportunities for a better understanding and eventually controlling of the malignance. However, we are still in the very early stage of information accumulation concerning the tumor associated changes in DNA methylation pattern. A number of excellent recent reviews have covered this issue in depth. Therefore, this review will summarize our recent data on DNA methylation profiling in cancers. Perspectives for the future direction in this dynamic and exciting field will also be given.


  • Open Access

    Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma

    by Jian Yu, Hongyu Zhang, Jun Gu, Song Lin, Junhua Li, Wei Lu, Yifei Wang, Jingde Zhu

    Background: Astrocytoma is a common aggressive intracranial tumor and presents a formidable challenge in the clinic. Association of altered DNA methylation patterns of the promoter CpG islands with the expression profile of cancer-related genes, has been found in many human tumors. Therefore, DNA methylation status as such may serve as an epigenetic biomarker for both diagnosis and prognosis of human tumors, including astrocytoma. Methods: We used the methylation specific PCR in conjunction with sequencing verification to establish the methylation profile of the promoter CpG island of thirty four genes in astrocytoma tissues from fifty three patients (The WHO grading:. I: 14, II: 15, III: 12 and IV: 12 cases, respectively). In addition, compatible tissues (normal tissues distant from lesion) from three non-astrocytoma patients were included as the control. Results: Seventeen genes (ABL, APC, APAF1, BRCA1, CSPG2, DAPK1, hMLH1, LKB1, PTEN, p14 ARF , p15 INK4b , p27 KIP1 , p57 KIP2 , RASSF1C, RB1, SURVIVIN, and VHL) displayed a uniformly unmethylated pattern in all the astrocytoma and non-astrocytoma tissues examined. However, the MAGEA1 gene that was inactivated and hypermethylated in non-astrocytoma tissues, was partially demethylated in 24.5% of the astrocytoma tissues (co-existence of the hypermethylated and demethylated alleles). Of the astrocytoma associated hypermethylated genes, the methylation pattern of the CDH13, cyclin a1, DBCCR1, EPO, MYOD1, and p16 INK4a genes changed in no more than 5.66% (3/53) of astrocytoma tissues compared to non-astrocytoma controls, while the RASSF1A, p73, AR, MGMT, CDH1, OCT6,, MT1A, WT1, and IRF7 genes were more frequently hypermethylated in 69.8%, 47.2%, 41.5%, 35.8%, 32%, 30.2%, 30.2%, 30.2% and 26.4% of astrocytoma tissues, respectively. Demethylation mediated inducible expression of the CDH13, MAGEA1, MGMT, p73 and RASSF1A genes was established in an astrocytoma cell line (U251), demonstrating that expression of these genes is likely regulated by DNA methylation. AR gene hypermethylation was found exclusively in female patients (22/27, 81%, 0/26, 0%, P < 0.001), while the IRF7 gene hypermethylation preferentially occurred in the male counterparts (11/26, 42.3% to 3/27, 11%, P < 0.05). Applying the mathematic method "the Discovery of Association Rules", we have identified groups consisting of up to three genes that more likely display the altered methylation patterns in concert in astrocytoma. Conclusions: Of the thirty four genes examined, sixteen genes exhibited astrocytoma associated changes in the methylation profile. In addition to the possible pathological significance, the established concordant methylation profiles of the subsets consisting of two to three target genes may provide useful clues to the development of the useful prognostic as well as diagnostic assays for astrocytoma.


  • A novel protein-DNA interaction involved with the CpG dinucleotide at −30 upstream is linked to the DNA methylation mediated transcription silencing of the MAGE-A1 gene

    by Jie Zhang, Jian Yu, Jun Gu, Bao Mei Gao, Ying Jun Zhao, Peng Wang, Hong Yu Zhang, Jing De Zhu

    Cell death and differentiation is a monthly research journal focused on the exciting field of programmed cell death and apoptosis. It provides a single accessible source of information for both scientists and clinicians, keeping them up-to-date with advances in the field. It encompasses programmed cell death, cell death induced by toxic agents, differentiation and the interrelation of these with cell proliferation.


    • 1 May 2004
      • Vol. 39  (5) , 338-41

    [Study of GE7-transferring system mediated beta-galactosidase gene transfer in a rat model of ovarian tumor by intraarterial route].

    by Wei Jiang, Cong-Jian Xu, Zhi-Min Shao, Wen-Jiang Zhou, Xiao-Xia Liu, Pei-Kun Tian, Jing-De Zhu, Jian-Ren Gu

    To investigate the efficiency and targeting of the GE7 system mediated gene transfer in the chemically induced ovarian tumor by intraarterial route. Animal models were chemically induced by 7,12-dimethylbenz[a]anthracene (DMBA). GE7-polylysine/beta-galactosidase (beta-gal)/polylysine-HA20 complexes were constructed. Fifteen rats with induced ovarian tumor were divided into three groups, the complexes were injected through ovarian artery and tail vein, respectively. The tumor, heart, liver, spleen, lung and kidney were obtained at 72 h. X-gal staining was used to check expression of beta-gal. beta-gal was expressed strongly and well-distributed in tumor in the first group, and stained blue in the liver, spleen, lung and kidney, but much weaker than that of tumor. In the second group, beta-gal was expressed in the tumor, and weakly expressed in the liver, none was detected in the other organs. In the third group beta-gal was detected in the lung slightly, none was detected in the tumor and other organs. When GE7 complexes were administrated through ovarian artery, the introduced gene expressed preferentially in ovary. This result was the basis of intraarterial administration of therapeutic gene to treat ovarian cancer.

  • Open Access

    Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis

    by Xiao-Li Xu, Jian Yu, Hong-Yu Zhang, Meng-Hong Sun, Jun Gu, Xiang Du, Da-Ren Shi, Peng Wang, Zhen-Hua Yang, Jing-De Zhu

    Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis


  • Open Access

    Methylation profile of the promoter CpG islands of 14 “drug-resistance” genes in hepatocellular carcinoma

    by Sheng Ding, Bang-Dong Gong, Jian Yu, Jun Gu, Hong-Yu Zhang, Zu-Bin Shang, Qi Fei, Peng Wang, Jing-De Zhu

    Methylation profile of the promoter CpG islands of 14 “drug-resistance” genes in hepatocellular carcinoma


  • Methylation profiling of twenty four genes and the concordant methylation behaviours of nineteen genes that may contribute to hepatocellular carcinogenesis

    by Jian Yu, Hong Yu Zhang, Zhen Zhong Ma, Wei Lu, Yi Fei Wang, Jingde Zhu

    Cell death and differentiation is a monthly research journal focused on the exciting field of programmed cell death and apoptosis. It provides a single accessible source of information for both scientists and clinicians, keeping them up-to-date with advances in the field. It encompasses programmed cell death, cell death induced by toxic agents, differentiation and the interrelation of these with cell proliferation.


  • Open Access

    Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis

    by Jian Yu, Min Ni, Jian Xu, Hongyu Zhang, Baomei Gao, Jianren Gu, Jianguo Chen, Lisheng Zhang, Mengchao Wu, Sushen Zhen, et al.

    Hepatocellular carcinoma (HCC) presents one of the major health threats in China today. A better understanding of the molecular genetics underlying malignant transformation of hepatocytes is critical to success in the battle against this disease. The methylation state of C5 of the cytosine in the CpG di-nucleotide that is enriched within or near the promoter region of over 50 % of the polymerase II genes has a drastic effect on transcription of these genes. Changes in the methylation profile of the promoters represent an alternative to genetic lesions as causative factors for the tumor-specific aberrant expression of the genes. We have used the methylation specific PCR method in conjunction with DNA sequencing to assess the methylation state of the promoter CpG islands of twenty genes. Aberrant expression of these genes have been attributed to the abnormal methylation profile of the corresponding promoter CpG islands in human tumors. While the following sixteen genes remained the unmethylated in all tumor and normal tissues: CDH1, APAF1, hMLH1, BRCA1, hTERC, VHL, RARβ, TIMP3, DAPK1, SURVIVIN, p14ARF, RB1, p15INK4b, APC, RASSF1c and PTEN, varying degrees of tumor specific hypermethylation were associated with the p16INK4a , RASSF1a, CASP8 and CDH13 genes. For instance, the p16INK4a was highly methylated in HCC (17/29, 58.6%) and less significantly methylated in non-cancerous tissue (4/29. 13.79%). The RASSF1a was fully methylated in all tumor tissues (29/29, 100%), and less frequently methylated in corresponding non-cancerous tissue (24/29, 82.75%). Furthermore, co-existence of methylated with unmethylated DNA in some cases suggested that both genetic and epigenetic (CpG methylation) mechanisms may act in concert to inactivate the p16INK4a and RASSF1a in HCC. Finally, we found a significant association of cirrhosis with hypermethylation of the p16INK4a and hypomethylation of the CDH13 genes. For the first time, the survey was carried out on such an extent that it would not only provide new insights into the molecular mechanisms underscoring the aberrant expression of the genes in this study in HCC, but also offer essential information required for a good methylation-based diagnosis of HCC.